WHC is still in active development. Read this to understand our approach.
depiction of PCOBBVZJEWWZFR-UHFFFAOYSA-N.svg
isomerdesign

Retigabine

Check on isomerdesign

pubchem

Retigabine

Check on pubchem

drugmap

Retigabine

Check on drugmap

Data

InChI: InChI=1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21)

Synonyms: AW21-360,Retigabine-[d4] Dihydrochloride,CHEBI:68584,D 20443,DB04953,Carbamic acid, (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)-, ethyl ester,CHEMBL41355,EZOGABINE [MI],Ezogabine (USAN),[2-Amino-4-[[(4-fluorophenyl)methyl]amino]phenyl]-carbamate,CCG-267503,CARBAMIC ACID, (2-AMINO-4-(((4-FLUORO-PHENYL)METHYL)AMINO)PHENYL)-ETHYL ESTER,Trobalt, Ethyl (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)carbamate,EZOGABINE [VANDF],[2-Amino-4-(4-fluoro-benzylamino)-phenyl]-carbamic acid ethyl ester,Potiga,AWD21-360,Ezogabine [USAN],N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester,GW 582892X, GKE-841, D-23129, D 20443,GKI 841, Retigabine [USAN],GW-582892X,BCP0726000089,N-(2-amino-4-[fluorobenzylamino]-phenyl) carbamic acid|D-23129,s4733,N03AX21,Retigabine (INN),HSDB 8171,RETIGABINE [WHO-DD],2-AMINO-4-(4-FLUORBENZYLAMINO)-1-ETHOXYCARBONYLAMINOBENZENE,HMS3748I09,WAY-143841,12G01I6BBU,ethyl 2-amino-4-(4-fluorobenzylamino)phenylcarbamate,Retigabin,Potiga (TN),D-23129,CS-0990,AMY18466, ADD-230001,Ethyl (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)carbamate,D09569,EZOGABINE [ORANGE BOOK], Ethyl 2-amino-4-((p-fluorobenzyl)amino)carbanilate,RETIGABINE [MART.],150812-12-7,Ethyl [2-amino-4-[[(4-fluorophenyl)methyl]amino]phenyl]carbamate,KE-0201,NCGC00346739-05, D 23129,MFCD04307735,GKE-841,ZINC16154,D 23129,HMS3885L20,812R127, Ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate, [2-Amino-4-[[(4-fluorophenyl)methyl]amino]phenyl]-carbamate,RETIGABINE [EMA EPAR],N-(2-amino-4-(4-fluorobenzylamino)-phenyl)carbamic acid ethylester,AWD-21360,DEA No. 2779,ZINC00016154, KE-0201,Potiva,DTXSID40164615,Retigabine solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material,SCHEMBL20835,Ezogabine,Retigabine, analytical standard,GW582892X,ethyl N-(2-amino-4-{[(4-fluorophenyl)methyl]amino}phenyl)carbamate,Q-101418,RTG,FBX,HY-15471, N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester,Q2146170,ADD-230001, Trobalt, D-20443,GTPL2601,N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester,UNII-12G01I6BBU,Ethyl 2-amino-4-((p-fluorobenzyl)amino)carbanilate,ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate,ethyl N-[2-azanyl-4-[(4-fluorophenyl)methylamino]phenyl]carbamate,FT-0601527, Carbamic acid, (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)-, ethyl ester, Ethyl N-(2-amino-4-(4-fluorobenzylamino)phenyl)carbamate hydrochloride,Retigabine,AC-6908,EX-A2203, N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester,NCGC00346739-06,A809076,Retigabine,D2312, D-23129,Retigabine, >=98% (HPLC),Retigabine [INN],N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamic acid ethyl ester,ethyl {2-amino-4-[(4-fluorobenzyl)amino]phenyl}carbamate,Retigabine (1.0 mg/mL in Acetonitrile),WAY 143841,BCP04194,AKOS015895311, Potiga,BDBM50143558,n-[2-amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid ethyl ester,NCGC00346739-01

Estimated data

Solubility: -3.711 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 53.5% (prediction based on www.mdpi.com)

Similarities

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.